Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Peginterferon Alfa-2a + Ribavirin in CHC with Compensated LC
NCT00304551Phase 3Completed
- Sponsor
- Chugai Pharmaceutical Co., Ltd.
- Start
- Jun 2006
- Primary completion
- Dec 2009
- Modality
- rProtein (Recombinant Protein), Biologic
- Countries
- 1
01
Overview
A Phase 3 trial of peginterferon alfa-2a in hepatitis C (HCV), Liver cirrhosis (LC), sponsored by Chugai Pharmaceutical Co., Ltd.. Started Jun 2006; status: completed.
02
Drugs
peginterferon alfa-2a
03
Conditions
hepatitis C (HCV)Liver cirrhosis (LC)
Beyond the preview
Go deeper on NCT00304551.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00304551.